Eribulin Does Not Prevent Epithelial-to-Mesenchymal Transition in HT-29 Intestinal Epithelial Cells

2Citations
Citations of this article
7Readers
Mendeley users who have this article in their library.
Get full text

Abstract

Background: Fistula formation affects up to 50% of Crohn's disease (CD) patients and causes considerable morbidity. Current pharmacological management mainly includes antibiotics, immunosuppressives, and anti-TNF antibodies. CD fistulas develop from intestinal epithelial cells undergoing epithelial-to-mesenchymal transition (EMT). TGFβ, the most important inducer of EMT, is detectable around CD fistula tracts and induces expression of the EMT-associated transcription factors SNAIL1 and SLUG as well as of IL-13. Conversely, together with TNF, IL-13 induces the expression of the transcription factor Ets-1 and β6-integrin, which are associated with cell invasiveness. Eribulin is a synthetic derivative of halichondrin B, a large polyether macrolide, which reverses EMT in triple-negative breast cancer (TNBC) cells. Here, we investigated whether Eribulin might be a potential therapeutic option for CD fistulas via the inhibition of EMT. Summary: Chronic treatment with high concentrations of Eribulin (> 5 ng/ml) is toxic for intestinal epithelial cells (IEC), and Eribulin treatment does not decrease the mRNA expression of EMT markers in HT-29 monolayers nor prevent EMT in HT-29 spheroids. Together with TNF, Eribulin induces the expression of vimentin and SLUG mRNA in HT-29 spheroids but concomitantly also promotes E-cadherin expression. Key Messages: Our data suggest that the previously reported antimetastatic effect of Eribulin in TNBC by reversing EMT does not apply to IEC. Interestingly, Eribulin promotes E-cadherin expression, suggesting an additional mechanism. The increase of E-cadherin might point towards the described role for Eribulin in reversing EMT. Taken together, our data do not support a role for Eribulin as treatment option for CD-associated fistulas.

Cite

CITATION STYLE

APA

Leutenegger, M., Bruckner, R., Spalinger, M. R., Lang, S., Rogler, G., & Scharl, M. (2018). Eribulin Does Not Prevent Epithelial-to-Mesenchymal Transition in HT-29 Intestinal Epithelial Cells. Inflammatory Intestinal Diseases, 2(4), 211–218. https://doi.org/10.1159/000490052

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free